What's new

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 3, Status: Authorised

Apr 10, 2025 - 14:08
 0
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 3, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, ...

Next Article

Prada agrees to buy Versace in €1.25 billion deal

Related Posts

Procedures for monograph and list entry establishment

Procedures for monograph and list entry establishment

Feb 14, 2025  0

Orphan designation: Trehalose Treatment of neuronal ceroid lipofuscinosis, 19/10/2020 Withdrawn

Orphan designation: Trehalose Treatment of neuronal cer...

Mar 12, 2025  0

Human medicines European public assessment report (EPAR): Efient, prasugrel, Date of authorisation: 24/02/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0